Opinion|Videos|November 21, 2024
Importance of Genetic Testing for Pediatric Epilepsy Diagnosis and Treatment Decisions
Author(s)John Michael Schreiber, MD
Key Takeaways
- Genetic testing enhances diagnostic accuracy in pediatric epilepsy, allowing for personalized treatment and better prognostic predictions.
- Interpreting genetic test results is challenging due to complex data, variants of uncertain significance, and the necessity for genetic counseling.
John Michael Schreiber, MD, describes the benefits of genetic testing for pediatric epilepsy diagnoses, noting the challenges associated with interpreting test results, and highlights key differences between genetic tests and their implications for clinical decisions, discussing how a genetic diagnosis can inform and guide epilepsy treatment.
Advertisement
Episodes in this series
- Please describe the benefits of genetic testing in regard to pediatric epilepsy diagnoses.
- What are some of the challenges when interpreting test results?
- Please highlight key differences between genetic tests when interpreting results and how they may impact clinical decisions.
- How might a genetic diagnosis inform epilepsy treatment?
- How might a genetic diagnosis inform epilepsy treatment?
Advertisement
Related to this article
FDA approves once-daily oral tavapadon for Parkinson disease, a first-in-class D1/D5 partial agonist that improves motor function and ON time, with key safety warnings.
In a discrete choice experiment, somnolence risk and short-term efficacy were the top factors driving vesicular monoamine transporter 2 inhibitor selection for tardive dyskinesia in patients aged 55 years and older.
Here's some of what is coming soon to NeurologyLive® this week.
The FDA extended its review of relutrigine for SCN2A- and SCN8A-related epilepsies by three months, pushing the PDUFA date to December 27, 2026.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is clinical trial results in Alzheimer disease!
In recognition of International Ataxia Awareness Day, observed annually on September 25, NeurologyLive® reviews 6 investigational agents in clinical development across ataxia-related disorders.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 25, 2026.
MS Compass: Guiding Clinical Care, a podcast hosted by neuroimmunologist Lindsay Ross, MD, brings you an exclusive interview with Rachel Galioto, PhD. [LISTEN TIME: 33 minutes]
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Extends Relutrigine Review, Delays PDUFA to December
2
Azetukalner NDA Submitted, EMA Gives Approval Recommendation to Ocrelizumab, Phase 3 FUSION Trial Meets End Points
3
What's Next in Ataxia: Pipeline Overview of Investigational Therapeutics
4
SKY-0515 Shows Sustained Benefit at 15 Months in Huntington Disease
5